HomeBIOVF • OTCMKTS
add
Swedish Orphan Biovitrum AB (publ)
Previous close
$28.30
Year range
$22.40 - $32.25
Market cap
103.24B SEK
Avg Volume
37.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 6.89B | 33.40% |
Operating expense | 3.52B | 4.14% |
Net income | 1.46B | 1,457.45% |
Net profit margin | 21.24 | 1,067.03% |
Earnings per share | 4.31 | 713.21% |
EBITDA | 3.00B | 89.53% |
Effective tax rate | 14.49% | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 594.00M | -12.39% |
Total assets | 72.20B | -4.47% |
Total liabilities | 35.09B | -14.71% |
Total equity | 37.11B | — |
Shares outstanding | 343.44M | — |
Price to book | 0.26 | — |
Return on assets | 7.15% | — |
Return on capital | 9.59% | — |
Cash Flow
Net change in cash
| (SEK) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 1.46B | 1,457.45% |
Cash from operations | 1.20B | 13.52% |
Cash from investing | -2.20B | -431.88% |
Cash from financing | 860.00M | 211.11% |
Net change in cash | -185.00M | -65.18% |
Free cash flow | -3.51B | -219.76% |
About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Founded
1939
Website
Employees
1,814
